Investors

Envista And Curaeos Partner To Advance Dental Care

BREA, Calif., April 27, 2021 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced the establishment of a new partnership aimed at providing value-added solutions and a variety of services to Curaeos' fast-growing network of dental clinics across the Netherlands, Belgium, Denmark, Germany, and Italy.

Envista is focused on delivering Curaeos' clinics with the latest and most innovative dental solutions available from its leading brands including KaVo, Kerr, Nobel Biocare, and Ormco. The new partnership emphasizes Envista's shared purpose and commitment to help to empower Curaeos' dental practitioners in their mission to deliver high quality dental care to their patients, including access to a wide array of training and educational programs and initiatives spearheaded by the Curaeos Academy.

Chris Cools, CEO Curaeos, shared his enthusiasm for the partnership, "On our journey to become a leading European DSO and the first choice for patients and dental care professionals, we are committed to offer a superior patient experience and provide our patients with oral care, delivering both quality & convenience. To reach our goals, we are very happy to be able to join forces with Envista who is renowned for its world class products and services."

"We are looking forward to partnering with Curaeos to support the dental professionals within their network," Amir Aghdaei, CEO of Envista, stated.  "Curaeos' know-how in supporting dental clinics combined with our innovative portfolio of solutions will help deliver more predictable and productive outcomes, leading to outstanding dental care for more patients."

ABOUT ENVISTA HOLDINGS CORPORATION

Envista is a global family of more than 30 trusted dental brands, united by a shared purpose: to partner with professionals to improve lives.  Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.  Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers an estimated 90% of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile.  Envista companies, including KaVo Kerr, Nobel Biocare, and Ormco, partner with dental professionals to help them deliver the best possible patient care.  With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide.  Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.  For more information, please visit www.envistaco.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, the conditions in the U.S. and global economy, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, significant restrictions and/or potential liability based on tax implications of transactions with Danaher, security breaches or other disruptions of our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors,  and disruptions relating to war, terrorism, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2019 and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

SOURCE Envista Holdings Corporation

FOR FURTHER INFORMATION

Melissa Morrison
Director, Communication
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
Fax: (714) 817-5450

SOURCE Envista Holdings Corporation


Sign up and never miss an investor alert.

Sign up and never miss an investor alert.